FDA
-
-
-
-
-
-
-
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
-
-
-
-
-
-
-
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
-
-
-
-
-
-
-
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
-
-
-
-
-
-
-
Allarity receives FDA fast track designation for ovarian cancer drug
-
-
-
-
-
-
-
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
-
-
-
-
-
-
-
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
-
325,888 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

